Application of Circulating Tumor Cell (CTC) PD-L1 Detection in the Evaluation of Therapeutic Efficacy in Advanced NSCLC: A Retrospective Study

被引：0
|
作者：
Deng, Y. [1 ]
Huang, Y. [2 ]
Cai, S. [1 ]
Yu, Z. [1 ]
Guo, X. [1 ]
机构：
[1] Shenzhen Canc Hosp, Shenzhen, Peoples R China
[2] Cell Shenzhen, Shenzhen, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
NSCLC; circulating tumor cell; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.11A.11
引用
收藏
页码：S600 / S600
页数：1
相关论文
共 50 条
  • [31] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative
    Liu, Y.
    Cao, L.
    Che, X.
    Qiu, X.
    Li, Z.
    Yang, B.
    Wang, S.
    Qu, X.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532
  • [32] Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
    Lee, Heng-Huan
    Wang, Ying-Nai
    Xia, Weiya
    Chen, Chia-Hung
    Rau, Kun-Ming
    Ye, Leiguang
    Wei, Yongkun
    Chou, Chao-Kai
    Wang, Shao-Chun
    Yan, Meisi
    Tu, Chih-Yen
    Hsia, Te-Chun
    Chiang, Shu-Fen
    Chao, K. S. Clifford
    Wistuba, Ignacio I.
    Hsu, Jennifer L.
    Hortobagyi, Gabriel N.
    Hung, Mien-Chie
    CANCER CELL, 2019, 36 (02) : 168 - +
  • [33] Patient sex and response to PD-1/PD-L1 inhibitor therapy in advanced NSCLC - a retrospective bi-centric cohort study
    Brauner, Anna
    Lang, David
    Lamprecht, Bernd
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 (19-20) : 618 - 618
  • [34] A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors
    Zhang, Congjun
    Li, Jingjing
    Wu, Hongyang
    Huang, Wei
    Da, Liangshan
    Shen, Yuanyuan
    Sun, Guoping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [35] Monitoring PD-L1 expression on circulating tumor cells (CTCs) in patients with NSCLC treated with PD1 inhibitors.
    Guibert, Nicolas Marie
    Delaunay, Myriam
    Lusque, Amellie
    Gouin, Sandrine
    Boubekeur, Nadia
    Rouquette, Isabelle
    Clermont, Estelle
    Fourtoul, Aurelien
    Favre, Gilles
    Pradines, Anne
    Mazieres, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [36] Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
    Piedra, A.
    Barba Joaquin, A.
    Mosquera Martinez, J.
    Fernandez Bruno, M.
    Cordeiro Gonzalez, P.
    Sullivan, I. G.
    Riudavets Melia, M.
    Aguado Sorolla, M.
    Gallardo Melo, P.
    Martin Cullell, B.
    Gavira, J.
    Tapia, J. C.
    Romano, A.
    Bosma, F.
    Sanchez Del Rio, S.
    Sanz Beltran, J.
    Molina Perez, M. A.
    Serra Lopez, J.
    Garcia Campelo, M. R.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1053 - S1053
  • [37] Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy
    Peters, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S74 - S74
  • [38] Longitudinal evaluation of PD-L1 expression on circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab
    Ikeda, Mio
    Koh, Yasuhiro
    Teraoka, Shunsuke
    Sato, Koichi
    Tokudome, Nahomi
    Hayata, Atsushi
    Akamatsu, Hiroaki
    Ozawa, Yuichi
    Akamatsu, Keiichiro
    Endo, Katsuya
    Higuchi, Masayuki
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 83 - 83
  • [39] Characterization of PD-L1 expression in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patients
    Krupa, R.
    Lu, D.
    Harvey, M.
    Louw, J.
    Jendrisak, A.
    Marrinucci, D.
    Dittamore, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 45 - 45
  • [40] The efficacy of PD-L1 blockade on PD-L1 negative medulloblastoma is dependent on timing and the tumor microenvironment
    Allen, Frederick
    Dorand, Rodney Dixon
    Rauhe, Peter
    Petrosiute, Agne
    Huang, Alex Y.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
12345